Sickle Cell Disease Treatment Market Size, Share, Growth Analysis, By Treatment type(Pharmaceuticals and supportive care), By End user(Hospitals, clinics, research institutes, and others), By Region - Industry Forecast 2024-2031

Drivers

Rising Incidence of Sickle Cell Disease 

• Genetic predisposition and lack of early detection have resulted in a major hike in incidence of sickle cell disease around the world. Africa, India, and the Middle East are projected to key countries where the prevalence of sickle cell disease is high thereby making them highly opportune markets for sickle cell disease treatment providers as well. 

Advancements in Genetic Research 

• Gene therapies and gene therapeutics have come a long way and are continually advancing owing to high investments in their R&D. These advancements have allowed researchers and doctors to understand sickle cell disease better and potentially even treat it by modifying the patient’s DNA to reduce complications and provide a long-term treatment as compared to a symptomatic one. 

Restraints 

Limited Awareness and Diagnosis 

• People are not aware regarding the symptoms of sickle cell disease and this lack of awareness has translated into late diagnosis. Moreover, inadequate diagnostic infrastructure also resulted in multiple cases going undiagnosed or are diagnosed too late for optimal intervention thereby impeding the demand for sickle cell disease treatment going forward.  

Safety Concerns with Novel Treatments 

• While novel sickle cell disease treatment and therapeutics offer significant promise, they also come with a long list of potential side effects and inadequate information about their long-term impact on human health. Moreover, complying with sickle cell disease treatment safety standards is also a key issue that is estimated to inhibit the adoption of novel treatments and slow down sickle cell disease treatment market growth in the future.